Angela Watson, DO
Internal Medicine · Memphis, TNNPI 1275601346
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (51.9%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Lilly USA, LLC accounts for 72.3% of it on its own, with 43 other manufacturers making up the rest. 2025 is the largest year on record at $23,982, more than ten times the $1,759 reported in 2019. Among internal medicine clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 516 payments — averaging $62.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$23K
- Merz North America, Inc.$1K
- Novo Nordisk$1K
- Astellas Pharma US Inc$614
- Otsuka America Pharmaceutical, Inc.$563
- Sanofi-aventis U.S. LLC$499
- plus $5K from 38 others
What the payments were for
- Speaking & faculty fees$16,80052%
- Travel & lodging$5,31916%
- Food & beverage$9,92131%
- Education$3051%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$32,344 in reported general payments places this provider in the 95th percentile of 2,216 internal medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 1,187 | $411,781 |
| XareltoRivaroxaban | 338 | $105,739 |
| OzempicSemaglutide | 80 | $101,198 |
| JanuviaSitagliptin Phosphate | 235 | $96,157 |
| LinzessLinaclotide | 92 | $55,134 |
| IngrezzaValbenazine Tosylate | 15 | $53,178 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 60 | $51,921 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 12 | $50,501 |
| MounjaroTirzepatide | 34 | $50,151 |
| NuedextaDextromethorphan Hbr/Quinidine | 38 | $33,557 |
| Levetiracetam | 579 | $31,623 |
| Atorvastatin Calcium | 1,905 | $29,958 |
| JardianceEmpagliflozin | 50 | $27,355 |
| FarxigaDapagliflozin Propanediol | 35 | $22,959 |
| EntrestoSacubitril/Valsartan | 56 | $22,336 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $467 | $411,7811,187 claims |
| MerckJanuvia, Janumet, Janumet Xr | $403 | $128,799273 claims |
| Novo NordiskOzempic, Rybelsus | $1,035 | $114,90893 claims |
| Johnson & JohnsonXarelto | $170 | $105,739338 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $411 | $66,02196 claims |
| Lilly USA, LLCMounjaro, Trulicity | $23,380 | $60,99154 claims |
| AbbVieLinzess | $184 | $55,13492 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $20 | $53,17815 claims |
| AstraZenecaFarxiga, Brilinta, Lokelma | $458 | $51,719159 claims |
| GileadGenvoya | $35 | $50,50112 claims |
| Boehringer IngelheimJardiance, Tradjenta | $235 | $49,30374 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $59 | $33,55738 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,216 internal medicine providers in Tennessee.
Other internal medicine in Memphis
- Phillip NorthcrossMemphis$39K
- William CushmanMemphis$23K
- Vanessa McKenzieMemphis$18K
- Brandon ToddMemphis$17K
- Cary FinnMemphis$16K
- Reuben AvilaMemphis$15K
- Jeremy AvilaMemphis$14K
- John AndersonNashville$1.5M
- Tracie WalkerJackson$488K
- Nathan TrenthamEtowah$404K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.